News

GSK and CureVac are making ‘next-generation’ vaccines that they say can tackle multiple COVID-19 variants at once

GlaxoSmithKline and CureVac have agreed to develop new vaccines that target multiple coronavirus variants. The shots, designed as boosters in case immunity from another vaccine drops, could be available 2022. Research suggests existing vaccines may be less effective against some coronavirus variants. Visit the Business section of Insider for more […]
GSK and CureVac are making ‘next-generation’ vaccines that they say can tackle multiple COVID-19 variants at once
News

GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.

GlaxoSmithKline and Sanofi have delayed the expected rollout of their COVID-19 vaccine to the final months of 2021. Interim results for human studies showed an “insufficient response in older adults,” the drugmakers said Friday – but they praised its effects in other age groups. The companies plan to repeat a […]
GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.
News

Major pharma companies rejected a 2017 EU proposal that could let vaccines for viruses like the coronavirus be developed before an outbreak

A 2017 proposal that would speed up vaccine production in the EU was blocked by major pharmaceutical companies,The Guardian reported. The proposal would fund improvements to testing, potentially allowing approval to be fast-tracked and for vaccines against viruses like the novel coronavirus to be developed before an outbreak begins. But […]
Major pharma companies rejected a 2017 EU proposal that could let vaccines for viruses like the coronavirus be developed before an outbreak
News

Pharma giant GSK just made a $5.1 billion bet on a cancer-drug maker

GlaxoSmithKline just agreed to acquire the cancer-drug maker Tesaro for $US5.1 billion in a bid to bulk up its cancer pipeline. Tesaro makes a drug called Zejula, which is used to treat ovarian cancer. GSK has been working to refresh its research-and-development strategy – in July it made a $US300 […]
Pharma giant GSK just made a $5.1 billion bet on a cancer-drug maker